N/A
Completed N=10
The Scleroderma Patient-centered Intervention Network (SPIN) Support Group Leader Education Program Feasibility Trial
Scleroderma · Systemic Sclerosis
Source: ClinicalTrials.gov NCT03508661 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcomePrimary: Participant Feedback on Usability of Program Materials — 10 Participants
Summary
Many people living with a rare disease turn to peer-led support groups to cope with their condition and access educational resources. Systemic sclerosis (SSc), or scleroderma, is a rare autoimmune connective tissue disease where peer-led support groups play an important role. There are currently approximately 200 SSc support groups in Canada and the US, most of which are led by people with SSc. Many SSc patients, however, cannot access support groups. In other cases, support groups are not sustained due to factors that include the burden on group leaders living with a serious, unpredictable disease and limited group leadership skills of some untrained leaders. Our partners from Scleroderma Canada and the Scleroderma Foundation in the US are committed to improving support group accessibility and effectiveness. These organizations maintain a list of active support groups, but currently do not provide training or other resources to groups or their leaders. To address this gap, our team, including investigators and patients from the Scleroderma Patient-centered Intervention Network (SPIN), developed the Scleroderma Support group Leader EDucation (SPIN-SSLED) Program, which is designed to improve support group leader confidence and self-efficacy, reduce burnout, improve emotional well-being, and improve health-related quality of life.
In the planned full-scale randomized controlled trial (RCT) that will follow our feasibility trial, we will evaluate whether the SPIN-SSLED Program is effective in improving SSc support group leaders' self-efficacy for carrying out their leader role (primary) and if it reduces burnout, improves emotional well-being, and improves health-related quality of life (secondary). Thus, the SPIN-SSLED Feasibility Trial answers the following research questions: (1) Is a full-scale SPIN-SSLED RCT feasible? (2) Are adaptations needed to the research design for the planned full-scale RCT? (3) Are there ways to improve the SPIN-SSLED Program for delivery in the planned full-scale RCT based on input of support group leaders who participate in the feasibility trial?
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Participant Feedback on Usability of Program Materials |
10 | — |
| PRIMARY Participant Feedback on Ease of Use of the Go-To Videoconferencing Program |
8; 2 | — |
| PRIMARY Participant Feedback on Ease of Use of the Online Forum |
10; 0 | — |
| PRIMARY Personnel Requirements |
— | — |
| PRIMARY Duration of Management of Online Training Group Participation |
2 | — |
| PRIMARY Percentage of Topics Adequately Covered in the Sessions |
96; 4 | — |
| PRIMARY Number of Participants That Reported no Technological Problems |
8; 2 | — |
| SECONDARY The Scleroderma Support Group Leader Self-efficacy Scale (SSGLSS) |
1.7 | — |
| SECONDARY Personal Health Questionnaire (PHQ-8) |
0.38 | — |
| SECONDARY Patient Reported Outcomes Measurement Information System (PROMIS-29) Profile Version 2.0 |
0.45 | — |
| SECONDARY Oldenburg Burnout Inventory (OLBI) |
0.44 | — |
Eligibility Criteria
Inclusion Criteria
- Be a current SSc support group leader or have been identified by Scleroderma Canada or the Scleroderma Foundation as a new leader who will initiate a new support group
- Be available to participate at times when sessions are scheduled
- Be English-speaking
Exclusion Criteria
- Unable to use the internet to access and participate in training sessions or to complete study questionnaires online
Data sourced from ClinicalTrials.gov (NCT03508661). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.